Metabolic HealthGLP-1 Drugs Can Cause Rare but Serious Liver Injury — Here's What to Watch For
GLP-1 receptor agonists (GLP-1RAs) — medications like semaglutide and tirzepatide widely used for obesity and type 2 diabetes — are generally considered protective for the liver. However, a comprehensive review now identifies 31 case reports of suspected drug-induced liver injury (DILI) linked to these drugs, plus 232 DILI reports in the FDA's adverse event database and three terminated drug development programs due to liver safety concerns. Symptoms often mimicked common GLP-1 side effects, potentially delaying diagnosis. Most cases were severe (grade 4 enzyme elevations), and some progressed to acute liver failure. Liver injury resolved in most patients after stopping the drug. Women, patients with fatty liver disease, those losing weight rapidly, and those escalating doses may be at higher risk. Clinicians and patients should be aware this risk exists, even though it appears rare.
